Pricing of multiple dosage prescription medications: An analysis of the Ontario Drug Benefit Formulary
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Ernst R. Berndt, 2002. "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 45-66, Fall.
- G Michael Allan & Joel Lexchin & Natasha Wiebe, 2007. "Physician Awareness of Drug Cost: A Systematic Review," PLOS Medicine, Public Library of Science, vol. 4(9), pages 1-11, September.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Jaume Puig-Junoy, 2012. "Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?," Applied Health Economics and Health Policy, Springer, vol. 10(6), pages 441-451, November.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008.
"Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy,"
NBER Working Papers
14567, National Bureau of Economic Research, Inc.
- Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008. "Pharmaceutical industry, drug quality and regulation. Evidence from US and Italy," CEIS Research Paper 138, Tor Vergata University, CEIS, revised 16 Dec 2008.
- Castanheira, Micael & Ornaghi, Carmine & Siotis, Georges, 2019.
"The unexpected consequences of generic entry,"
Journal of Health Economics, Elsevier, vol. 68(C).
- Micael Castanheira De Moura & Carmine Ornaghi & Georges Siotis, 2019. "The Unexpected Consequences of Generic Entry," Working Papers ECARES 2019-21, ULB -- Universite Libre de Bruxelles.
- Micael Castanheira De Moura & Georges Siotis & Carmine Ornaghi, 2019. "The Unexpected Consequences of Generic Entry," ULB Institutional Repository 2013/298643, ULB -- Universite Libre de Bruxelles.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Jason C. Hsu & Eduardo S. Schwartz, 2003. "A Model of R&D Valuation and the Design of Research Incentives," NBER Working Papers 10041, National Bureau of Economic Research, Inc.
- Glazer Jacob & Huskamp Haiden A. & McGuire Thomas G., 2012. "A Prescription for Drug Formulary Evaluation: An Application of Price Indexes," Forum for Health Economics & Policy, De Gruyter, vol. 15(1), pages 1-26, March.
- Crown William H. & Berndt Ernst R. & Baser Onur & Finkelstein Stan N. & Witt Whitney P. & Maguire Jonathan & Haver Kenan E., 2004.
"Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?,"
Forum for Health Economics & Policy, De Gruyter, vol. 7(1), pages 1-35, January.
- William H. Crown & Ernst R. Berndt & Onur Baser & Stan N. Finkelstein & Whitney P. Witt & Jonathan Maguire & Kenan E. Haver, 2004. "Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?," NBER Chapters, in: Frontiers in Health Policy Research, Volume 7, pages 95-128, National Bureau of Economic Research, Inc.
- William H. Crown & Ernst R. Berndt & Onur Baser & Stan N. Finkelstein & Whitney P. Witt, 2003. "Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?," NBER Working Papers 10062, National Bureau of Economic Research, Inc.
- G Michael Allan & Christina Korownyk & Kate LaSalle & Ben Vandermeer & Victoria Ma & Douglas Klein & Donna Manca, 2010. "Do Randomized Controlled Trials Discuss Healthcare Costs?," PLOS ONE, Public Library of Science, vol. 5(8), pages 1-5, August.
- Ben van Hout & Jolian McHardy & Aki Tsuchiya, 2015. "Patent Purchase as a Policy for Pharmaceuticals," Working Papers 2015007, The University of Sheffield, Department of Economics.
- Siotis, Georges & Ornaghi, Carmine & Castanheira, Micael, 2019.
"Market Definition and Competition Policy Enforcement in the Pharmaceutical Industry,"
CEPR Discussion Papers
14035, C.E.P.R. Discussion Papers.
- Georges Siotis & Carmine Ornaghi & Micael Castanheira De Moura, 2020. "Market Definition and Competition Policy Enforcement in the Pharmaceutical Industry," Working Papers ECARES 2020-49, ULB -- Universite Libre de Bruxelles.
- Gauri Billa & Karan Thakkar & Sarita Jaiswar & Dinesh Dhodi, 2014. "A Cross-Sectional Study to Evaluate the Awareness and Attitudes of Physicians Towards Reducing the Cost of Prescription Drugs, Mumbai," Applied Health Economics and Health Policy, Springer, vol. 12(2), pages 125-137, April.
- Barkowski, Scott, 2021. "Physician Response to Prices of Other Physicians: Evidence from a Field Experiment," MPRA Paper 108966, University Library of Munich, Germany.
- Stefanie Heinzle, 2012. "Disclosure of Energy Operating Cost Information: A Silver Bullet for Overcoming the Energy-Efficiency Gap?," Journal of Consumer Policy, Springer, vol. 35(1), pages 43-64, March.
- Jennifer Rice, 2009. "The influence of managed care on generic prescribing rates: an analysis of HMO physicians," Applied Economics, Taylor & Francis Journals, vol. 43(7), pages 787-796.
- Ida Iren Eriksen & Hans Olav Melberg & Berit Bringedal, 2013. "Norwegian Physicians’ Knowledge of the Prices of Pharmaceuticals: A Survey," PLOS ONE, Public Library of Science, vol. 8(9), pages 1-1, September.
- Königbauer, Ingrid, 2006. "Dealing with Rising Health Care Costs: The Case of Pharmaceuticals," Munich Dissertations in Economics 5640, University of Munich, Department of Economics.
- Ernst R. Berndt & Joseph P. Newhouse, 2010.
"Pricing and Reimbursement in U.S. Pharmaceutical Markets,"
NBER Working Papers
16297, National Bureau of Economic Research, Inc.
- Newhouse, Joseph Paul & Berndt, Ernst R., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Scholarly Articles 4450127, Harvard Kennedy School of Government.
- Berndt, Ernst R. & Newhouse, Joseph P., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series rwp10-039, Harvard University, John F. Kennedy School of Government.
- Limbrock Frank, 2011. "Pecuniary and Non-Pecuniary Incentives in Prescription Pharmaceuticals: The Case of Statins," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 11(2), pages 1-30, January.
- Martin Gaynor & Kate Ho & Robert J. Town, 2015.
"The Industrial Organization of Health-Care Markets,"
Journal of Economic Literature, American Economic Association, vol. 53(2), pages 235-284, June.
- Martin Gaynor & Kate Ho & Robert Town, 2014. "The Industrial Organization of Health Care Markets," NBER Working Papers 19800, National Bureau of Economic Research, Inc.
- Benjamin R. Handel & Kate Ho, 2021. "Industrial Organization of Health Care Markets," NBER Working Papers 29137, National Bureau of Economic Research, Inc.
- Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015.
"Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement,"
Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
- Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2011. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement," NBER Working Papers 17174, National Bureau of Economic Research, Inc.
- Magno, Cielo & Guzman, Ricardo Rafael S., 2019. "Drug price sensitivity among physicians in a developing healthcare system: Evidence from the Philippine market for statins and beta blockers," Economic Analysis and Policy, Elsevier, vol. 62(C), pages 268-279.
More about this item
Keywords
Dosage forms Drug costs Drug industry Formularies;Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:91:y:2009:i:2:p:142-147. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.